Secondary Logo

Share this article on:

Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients

Erratum

doi: 10.1097/WNF.0000000000000318
Erratum

In the article, “Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients,” by Takeya Kitta, MD, PhD, Ichiro Yabe, MD, PhD, and Yukiko Kanno, MD, PhD, et al., in Clin Neuropharmacol Vol. 41, No. 3, pp. 98–102, several errors were made in the abstract:

The mean age of the patients was 66 years (61–80 years), not 73 years (61–77 years).

The Disease duration was 9 years (4–26 years), not 9 years (3 – 28 years).

The Motor symptoms were significantly better at 3 and 6 months and 1 year than at baseline (MDS-UPDRS part III: 30.0 ± 12.9 vs 10.9 ± 7.1, 13.8 ± 8.1, and 13.5 ± 7.0; P < 0.01), rather than at 12 months' administration (MDS-UPDRS part III: 30.0 ± 12.9 vs 13.8 ± 8.1; P < 0.01).

In addition, the KHQ-QOL score was calculated in the 9 domains, not 8, and should have included “Incontinence severity measures.”

Finally, Table 2 should have included the legend “*P < 0.05, significantly different from baseline.”

The authors apologize for the errors.

Kitta T, Yabe I, Kanno Y, et al. Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients. Clin Neuropharmacol 2018;41:98–102.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.